Amplyx pharmaceuticals announces management changes and financial backing for the clinical development of APX001

Submitted by HLeSueur on 13 February 2016

APX001 is a new broad-spectrum antifungal agent from Amplyx Pharmaceuticals, with a novel mechanism of action. New antifungal mechanisms are vital for the fight against the growing problem of resistance to existing antifungal treatments. APX001 has shown broad spectrum activity against infections caused by both Candida and Aspergillus in pre-clinical trials. Amplyx is developing IV and oral formulations and the drug is expected to enter clinical trials this year.

The funds provided by the new members of the management team will enable the clinical development of APX001 through to Phase 2 clinical trials.